real-time news and commentary for investors
Thursday, Sep 13
2012, 4:39 PM
Myrexis (MYRX) suspends development activity on all its programs, saying it's been unsuccessful...
Myrexis (MYRX) suspends development activity on all its programs, saying it's been unsuccessful to date in identifying and attracting third parties to whom it could out-license or sell assets for further development. In February, the company announced that it had suspended development activity on all of its preclinical and clinical programs, and retained Stifel Nicolaus Weisel to assist in reviewing and evaluating strategic alternatives.